Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells $101,868.30 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Trading Up 1.6%

Progyny stock opened at $25.19 on Thursday. The firm has a market cap of $1.93 billion, a PE ratio of 27.38, a P/E/G ratio of 1.71 and a beta of 0.99. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06. The stock’s 50 day simple moving average is $27.37 and its two-hundred day simple moving average is $24.74.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. During the same period in the previous year, the firm earned $0.19 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 1.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PGNY. Weiss Ratings cut Progyny from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Jefferies Financial Group set a $33.00 price target on Progyny in a report on Tuesday, September 8th. BTIG Research increased their price target on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. JPMorgan Chase & Co. boosted their price objective on Progyny from $27.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, August 21st. Finally, Barclays reduced their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.36.

Institutional Trading of Progyny

Several large investors have recently bought and sold shares of PGNY. Public Employees Retirement System of Ohio acquired a new position in shares of Progyny during the 2nd quarter worth approximately $29,000. Nykredit A S acquired a new stake in shares of Progyny in the second quarter valued at approximately $38,000. Hantz Financial Services Inc. lifted its position in Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after buying an additional 742 shares in the last quarter. IFP Advisors Inc boosted its stake in Progyny by 376.0% during the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after buying an additional 1,549 shares during the last quarter. Finally, Toth Financial Advisory Corp acquired a new position in Progyny during the second quarter worth $65,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.